Arbutus Biopharma (NASDAQ:ABUS) Announces Earnings Results, Misses Estimates By $0.04 EPS

Arbutus Biopharma (NASDAQ:ABUS) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.04), Zacks reports. Arbutus Biopharma had a negative return on equity of 68.18% and a negative net margin of 1,137.65%. The company had revenue of $1.76 million during the quarter, compared to analysts’ expectations of $2.54 million.

Arbutus Biopharma Trading Down 0.9%

Shares of NASDAQ:ABUS opened at $3.16 on Thursday. The stock has a fifty day simple moving average of $3.27 and a two-hundred day simple moving average of $3.39. The stock has a market capitalization of $605.08 million, a price-to-earnings ratio of -7.35 and a beta of 1.50. Arbutus Biopharma has a 12-month low of $2.71 and a 12-month high of $4.73.

Analyst Ratings Changes

A number of research firms have recently commented on ABUS. HC Wainwright restated a “buy” rating and issued a $5.00 target price on shares of Arbutus Biopharma in a research note on Tuesday, January 21st. Chardan Capital restated a “buy” rating and set a $5.00 target price on shares of Arbutus Biopharma in a report on Friday, March 28th. Finally, StockNews.com raised shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday, March 29th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $5.50.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.